Literature DB >> 7074796

Drug-induced conditioning in congestive heart failure.

C V Leier, P Huss, R P Lewis, D V Unverferth.   

Abstract

Continuous 72-hour infusions of dobutamine reportedly effect sustained clinical improvement in patients with congestive heart failure. This study was designed to determine if shorter, more frequent infusions, delivered in an outpatient setting, elicit a similar response. Twenty-six patients with moderately severe congestive heart failure were randomized, 11 into a control group and 15 into a dobutamine treatment group. Baseline data were collected for 4 weeks in each group. Thereafter, the dobutamine treatment group received 4-hour infusions of dobutamine weekly for 24 weeks. Systolic time intervals, echocardiography, cardiac index and treadmill exercise tolerance were used to follow the progress of the control and dobutamine treatment groups. The ratio of preejection period to left ventricular ejection time and the cardiac index did not change significantly in either group. The velocity of circumferential fiber shortening and the percent change in the minor axis of the left ventricle during systole improved modestly (p less than 0.05) above baseline in the dobutamine group after 14 weeks of treatment and above the corresponding control values (p less than 0.05) after 22 weeks. Exercise tolerance (duration) improved 25--51% (all p less than 0.05) above baseline in the dobutamine group compared with 10--17% (all p greater than 0.05 vs baseline) in the control group. Heart rate at maximal exercise did not change significantly from baseline for either group and did not differ significantly between the two groups. Functional classification improved in 12 of 15 dobutamine treatment patients and in only two of 11 control patients (p less than 0.05). In our patients with congestive heart failure, weekly 4-hour dobutamine infusions did not elicit a major change in resting left ventricular function; however, exercise performance and clinical status improved considerably.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7074796     DOI: 10.1161/01.cir.65.7.1382

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  16 in total

Review 1.  The role of anti-cytokine therapy in the failing heart.

Authors:  A Deswal; A Misra; B Bozkurt
Journal:  Heart Fail Rev       Date:  2001-03       Impact factor: 4.214

Review 2.  Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Catherine L Tacon; John McCaffrey; Anthony Delaney
Journal:  Intensive Care Med       Date:  2011-12-08       Impact factor: 17.440

3.  The search of an ideal oral positive inotropic agent.

Authors:  L B Tan
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Prevention of bedrest-induced physical deconditioning by daily dobutamine infusions. Implications for drug-induced physical conditioning.

Authors:  M J Sullivan; P F Binkley; D V Unverferth; J H Ren; H Boudoulas; T M Bashore; A J Merola; C V Leier
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

Review 5.  Drug treatment of heart failure.

Authors:  C T Dollery; L Corr
Journal:  Br Heart J       Date:  1985-09

Review 6.  Inotropic agents for heart failure: what if digoxin increases mortality?

Authors:  W J Remme
Journal:  Br Heart J       Date:  1994-09

Review 7.  Long-term intravenous inotropes in low-output terminal heart failure?

Authors:  Wolfgang von Scheidt; Matthias Pauschinger; Georg Ertl
Journal:  Clin Res Cardiol       Date:  2016-02-15       Impact factor: 5.460

8.  Effects of a single, 24-hour, low-dose intravenous dobutamine infusion on left ventricular myocardial performance index in congestive heart failure: A prospective, nonrandomized study.

Authors:  Melek Ulucam; Mehmet Emin Korkmaz; Haldun Muderrisoglu; Bulent Ozin; Aylin Yildirir; Egemen Tayfun; Alp Aydinalp
Journal:  Curr Ther Res Clin Exp       Date:  2005-01

Review 9.  The treatment of heart failure. A methodological review of the literature.

Authors:  G H Guyatt
Journal:  Drugs       Date:  1986-12       Impact factor: 9.546

Review 10.  Treatment of end stage dilated cardiomyopathy.

Authors:  J B O'Connell; C K Moore; H C Waterer
Journal:  Br Heart J       Date:  1994-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.